A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Last updated:
2026-08-22
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, TWO-PART, RANDOMIZED, OPEN-LABEL, ADAPTIVE STUDY COMPARING BMS- 986365 VERSUS INVESTIGATOR'S CHOICE OF THERAPY COMPRISING EITHER DOCETAXEL OR SECOND ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI), IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) - RECHARGE

Intervention/treatment:
BMS-986365 / ABIRATERONE / ENZALUTAMIDE / DOCETAXEL / PREDNISONE
Medical condition:
CASTRATION RESISTANT PROSTATE CANCER
Protocol code:
CA0711000
Control number:
293960
Status:
Recruiting
Approved:
February 14, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06764485
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: MALE
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

British Columbia

BC Cancer Kelowna
Kelowna, British Columbia, V1Y 5L3
RECRUITING
Name
Daygen Finch, Site 0304
Role
CONTACT
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 4E6
RECRUITING
Name
Kim Chi, Site 0152
Role
CONTACT
Phone:
6048776000

Nova Scotia

Local Institution - 0151
Halifax, Nova Scotia, B3H 2Y9
COMPLETED
Name
Ricardo Rendon, Site 0151
Role
CONTACT
Phone:
902-473-7969

Ontario

Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5
RECRUITING
Name
Daniel Khalaf, Site 0193
Role
CONTACT
Phone:
6048776000 ext676122

Quebec

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
Québec, Quebec, G1J 1Z4
RECRUITING
Name
Frederic Pouliot, Site 0150
Role
CONTACT
Phone:
4185254444
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski
Rimouski, Quebec, G5L 5T1
RECRUITING
Name
Samuel Nadeau, Site 0164
Role
CONTACT
Phone:
4187243000
Jewish General Hospital
Montreal, Quebec, H3T 1E2
RECRUITING
Name
April Rose, Site 0149
Role
CONTACT
Phone:
41694645015190
Local Institution - 0093
Chicoutimi, Quebec, G7H 5H6
COMPLETED
Name
Jose Luiz Guimaraes, Site 0093
Role
CONTACT
Phone:
418541-1000
McGill University Health Centre
Montreal, Quebec, H4A 3J1
RECRUITING
Name
Ramy Saleh, Site 0305
Role
CONTACT
Phone:
5149341934
Did you find what you were looking for?

Contacts and resources